ARTICLE | Clinical News
Herpes vaccine: Phase I/II
November 25, 2002 8:00 AM UTC
In a Mexican Phase I/II trial in 62 patients, one-year follow-up data showed the vaccine prevented all signs and symptoms of recurrent genital herpes in 43.5% of patients for 12-15 months. One-year da...